Five-Year Antimicrobial Resistance Patterns of Urinary Escherichia Coli at an Australian Tertiary Hospital: Time Series Analyses of Prevalence Data

Author Faculty (Discipline)


Document Type


Publication Date


Publication Details

This article was originally published as:

Fasugba, O., Mitchell B. G., Mnatzaganian, G., Das, A., Collignon, P., & Gardner, A. (2016). Five-year antimicrobial resistance patterns of urinary Escherichia coli at an Australian Tertiary hospital: Time series analyses of prevalence data. PLoS ONE, 11(10), 1-14. doi:10.1371/journal.pone.0164306

ISSN: 1932-6203


060501 Bacteriology| 060502 Infectious Agents| 111706 Epidemiology| 111716 Preventive Medicine

Avondale Research Centre

Lifestyle Research Centre

Reportable Items



This study describes the antimicrobial resistance temporal trends and seasonal variation of Escherichia coli (E. coli) urinary tract infections (UTIs) over five years, from 2009 to 2013, and compares prevalence of resistance in hospital- and community-acquired E. coli UTI. A cross sectional study of E. coli UTIs from patients attending a tertiary referral hospital in Canberra, Australia was undertaken. Time series analysis was performed to illustrate resistance trends. Only the first positive E. coli UTI per patient per year was included in the analysis.

A total of 15,022 positive cultures from 8724 patients were identified. Results are based on 5333 first E. coli UTIs, from 4732 patients, of which 84.2% were community acquired. Five-year hospital and community resistance rates were highest for ampicillin (41.9%) and trimethoprim (20.7%). Resistance was lowest for meropenem (0.0%), nitrofurantoin (2.7%), piperacillin-tazobactam (2.9%) and ciprofloxacin (6.5%). Resistance to amoxycillin-clavulanate, cefazolin, gentamicin and piperacillin-tazobactam were significantly higher in hospital- compared to community-acquired UTIs (9.3% versus 6.2%; 15.4% versus 9.7%; 5.2% versus 3.7% and 5.2% versus 2.5%, respectively). Trend analysis showed significant increases in resistance over five years for amoxycillin-clavulanate, trimethoprim, ciprofloxacin, nitrofurantoin, trimethoprim-sulphamethoxazole, cefazolin, ceftriaxone and gentamicin (P


Used by permission: the authors.

Copyright © 2016 Fasugba et al.This is an open access article distributed under the terms of the Creative Commons Attribution CC BY 4.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.